Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Genes and immunity 2022-12, Vol.23 (8), p.255-259
Hauptverfasser:	Van Gool, Stefaan W., Makalowski, Jennifer, Bitar, Michael, Van de Vliet, Peter, Schirrmacher, Volker, Stuecker, Wilfried
Format:	Artikel
Sprache:	eng
Schlagworte:	13 631/250/251/1567 631/250/2520 631/250/580 Adult Antineoplastic Agents, Alkylating - therapeutic use Biomedical and Life Sciences Biomedicine Brain Neoplasms - genetics Brain Neoplasms - therapy Brief Communication Cancer Research Chemoradiotherapy Dacarbazine - therapeutic use DNA Methylation DNA Modification Methylases - genetics DNA Modification Methylases - therapeutic use DNA Repair Enzymes - genetics DNA Repair Enzymes - therapeutic use Gene Expression Glioblastoma - drug therapy Glioblastoma - therapy Human Genetics Humans Immunology Immunotherapy Isocitrate Dehydrogenase - genetics Isocitrate Dehydrogenase - therapeutic use Medical prognosis Patients Retrospective Studies Survival Temozolomide Temozolomide - therapeutic use Tumor Suppressor Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients remains poor. Addition of Temozolomide (TMZ) to first-line local treatment shifted the median overall survival (OS) from 11.8 to 12.6 months. We retrospectively analyzed the value of individualized multimodal immunotherapy (IMI) to improve OS in these patients. All adults meeting the criteria and treated 06/2015–06/2021 were selected. Thirty-two patients (12f, 20m) had a median age of 47 y (range 18–69) and a KPI of 70 (50–100). Extent of resection was complete (11),
ISSN:	1476-5470 1466-4879 1476-5470
DOI:	10.1038/s41435-022-00162-y